根据 Insight 数据库「中国上市策略 & 时长预测」模块， 2025 年预计将有 40 款抗肿瘤新药首次在国内获批上市。本文将节选其中 15 个潜在重磅抗肿瘤新药信息进行分享，仅供读者参阅（以下排名不分先后）。强生：塔奎妥单抗 CD3 × ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based ...

Adc Therapeutics SA stock has reached a 52-week low, trading at $1.61, as the company faces a challenging market environment. According to InvestingPro analysis, the stock's RSI indicates oversold ...

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based on ...

ADC Therapeutics SA股票在公司面临市场挑战的环境下触及52周新低，交易价格为1.61美元。根据 InvestingPro ...

attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC ...

Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of a protease-cleavable maleimide tetrapeptide and topoisomerase which is an exatecan derivative, produced in Chinese hamster ovary cells by ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

TUB-030 consists of a humanized, Fc-silenced IgG1 antibody targeting 5T4 equipped with Tubulis’ proprietary Tubutecan technology, which is based on P5 conjugation chemistry and the topoisomerase-1 ...

此前拆过很多关于宜明昂科的核心管线——IMM01的细节，这款靶向CD47的融合蛋白解决了溶血问题后，为宜明昂科带来了非常高的热度。具体关于该靶点可以见文章《牛市创新药弹性第一股》。宜明昂科和康方都在针对CD47这个靶点苦下功夫，目的是为了让巨噬细胞配 ...